newsfilter
← Latest News
GlobeNewswire·

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with